Keeping Track: Early Thanks Given By ImmunoGen, Provention Bio; More PD-1/L1 Combo Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.
The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.
Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.